Anbio Biotechnology

What they do

The company operates in the In Vitro & In Vivo Diagnostic Substances industry (SIC 3841) from its principal executive offices in Frankfurt am Main, Germany. Its annual report on Form 20-F for the fiscal year ended December 31, 2025 was filed with the SEC on April 7, 2026, and Amendment No. 1 was filed April 9, 2026 solely to check the well-known seasoned issuer box on the cover page. The filing excerpts provided do not describe specific products, production facilities, or customer relationships.

Revenue drivers

• Not disclosed in provided excerpts — The filing text made available does not break out revenue by product line or segment; total annual revenue was $23.5M in 2022, $6.7M in 2023, $8.2M in 2024, and $8.6M in 2025.

Recent performance

Total revenue was $8.6M in 2025, up from $8.2M in 2024 but still well below the $23.5M reported in 2022. Net income rose to $6.4M in 2025 from $2.4M in 2024, and diluted EPS was $0.147 in 2025 versus $0.056 in 2024. Operating cash flow turned negative at -$6.7M in 2025, compared with positive $2.1M in 2024. At December 31, 2025, total assets were $30.2M, total liabilities were $87,836, and shareholders' equity was $30.2M, with cash and equivalents of $7.8M.

Strategy

The only stated purpose of the April 9, 2026 Form 20-F/A was to amend the cover page of the original annual report to indicate that the Company is a well-known seasoned issuer under Rule 405 of the Securities Act. The amendment states that no other changes were made to the Annual Report and that it does not reflect events occurring after the original filing. As a result, the provided excerpts do not describe any business strategy, product roadmap, or investment priorities.

Risks

• Revenue concentration in an undisclosed business — Because the excerpts do not identify specific products or segments, investors cannot assess what generated the $8.6M of 2025 revenue or how durable it is.
• Operating cash burn — Operating cash flow swung to -$6.7M in 2025 from +$2.1M in 2024, against a cash balance of $7.8M at year-end.
• Revenue volatility — Annual revenue fell from $23.5M in 2022 to $6.7M in 2023 and has only partially recovered to $8.6M in 2025.
• Limited disclosure in the amendment — The Form 20-F/A expressly states it does not update the Annual Report for events after April 7, 2026, so the information may be stale.

Outlook

The excerpts provided do not include forward-looking statements, guidance, or management commentary on future plans. The Form 20-F/A is administrative in nature and does not modify the operating disclosures of the original annual report. No outlook can be summarized from the source material.